Venclexta 50mg Tablet

Venclexta 50mg Tablet contains the active ingredient Venetoclax. Venclexta 50mg Tablet is an antineoplastic drug belonging to the class of BCL-2 inhibitors. It is used to treat adults with certain types of blood cancers, including chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). Specifically, it is indicated in CLL with a 17p deletion and in AML in patients who are unable to undergo intensive chemotherapy. Additionally, it may be used in combination with other medications to treat certain types of non-Hodgkin lymphoma. Venclexta 50mg Tablet works by inhibiting the BCL-2 protein, which promotes cancer cell death. This mechanism restores apoptosis (programmed cell death) by binding to BCL-2, displacing pro-apoptotic proteins, and initiating mitochondrial outer membrane permeabilisation, which triggers cell death. Do not take Venclexta 50mg Tablet if you are allergic to Venetoclax or any of the other ingredients in this medication. Before starting treatment, inform your doctor if you have kidney problems, a history of infections, or any blood-related disorders such as low white blood cell count or low platelet count. Ensure that your physician is aware of any past history of Tumour Lysis Syndrome (TLS) or if you are pregnant or planning to become pregnant, as Venclexta may harm the fetus. Venclexta 50mg Tablet should not be used in children or adolescents under 18 years of age.

Venclexta 50mg Tablet is used in the treatment of the following: Chronic lymphocytic leukaemia (CLL), including CLL with 17p deletion Acute myeloid leukaemia (AML) in adults who cannot undergo intensive chemotherapy Certain types of non-Hodgkin lymphoma, when combined with other medications

Venclexta 50mg Tablet works as a selective, orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. In CLL and AML cells, BCL-2 overexpression supports tumour cell survival and chemotherapy resistance by binding directly to BCL-2, Venclexta 50mg Tablet displaces pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilisation and activating caspases. Nonclinical studies demonstrate venetoclax’s cytotoxic effect on tumor cells overexpressing BCL-2.

Venclexta 50mg Tablet is administered orally. Do not break, chew, or crush the tablets. Follow the prescribed dosing schedule and consult your healthcare provider to determine the correct dosage. If you miss a dose, do not double the dose. Contact your healthcare provider for guidance.

Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them. Common side effects of Venclexta 50mg Tablet are Fatigue Anemia Nausea Diarrhea Low platelet count (thrombocytopenia) Low white blood cell count (neutropenia) Serious side effects of Venclexta 50mg Tablet are: Risk of death Tumor lysis syndrome (TLS) Kidney failure Need for dialysis treatment

Venclexta 50mg Tablet can cause serious side effects like Tumor Lysis Syndrome (TLS), neutropenia, and infections, requiring close monitoring and prophylactic treatment, especially during the ramp-up phase. It may also harm the fetus, so women of reproductive potential should avoid pregnancy during treatment. Regular blood counts are essential to detect neutropenia and live attenuated vaccines should be avoided. Follow your healthcare provider’s instructions carefully, stay hydrated, and notify your doctor immediately if you experience symptoms like fever or unusual tiredness